HealthDay News — A regional system of care seems beneficial for patients undergoing transcatheter aortic valve replacement (TAVR), according to a study published in the Dec. 28 issue of JACC: Cardiovascular Interventions.

Dion Stub, MBBS, PhD, from St. Paul’s Hospital in Vancouver, Canada, and colleagues implemented a regional system of care for patients undergoing TAVR in British Columbia, Canada, in a prospective observational cohort study involving 583 patients. Regionalization of care involved a centrally coordinated, funded, and evaluated program, which was led by a medical director and a multidisciplinary advisory team that oversaw planning, access to care, and quality of outcomes. On the basis of consensus provincial indications, heart teams performed risk-stratified case selection for transfemoral TAVR. Referrals for lower volume and more complicated procedures were concentrated at a single site.

The researchers found that transfemoral access and non-transfemoral access was performed in 85.6 and 14.4% of cases, respectively. In 7.4% of patients, transcatheter valve-in-valve procedures were performed for failed bioprosthetic valves. Overall, 66.2 and 32.4% of patients had a balloon-expandable and self-expanding valve inserted, respectively. The all-cause 30-day mortality was 3.5%; 3.1% and 1.9% of patients experienced all-cause in-hospital mortality and disabling stroke, respectively. The median length of stay was three days; most patients (92.8%) were discharged home.

“This experience demonstrates the potential benefits of a regional system of care for TAVR,” the authors write.

Several authors disclosed financial ties to the medical device industry.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)